Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients

Hypertension Clinical Trial

— MG600  

Official title:

Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01151683
• Other study ID #: MG600
• Status: Completed
• Phase: Phase 4
• First received: June 25, 2010
• Last updated: January 4, 2013
• Start date: March 2010
• Est. completion date: November 2012

Study information

• Verified date: January 2013
• Source: Rio de Janeiro State University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Introduction: Magnesium has been the target for many experimental and clinical studies due to the negative correlation between its serum and intracellular levels and the prevalence of hypertension and other cardiovascular diseases.

Objective: To evaluate the effects of magnesium supplementation in hypertensive patients who are under diuretic treatment, including correlation of clinical and nutritional parameters with structural and functional aspects of the macrocirculation.

Methods: A prospective, randomized, double blind, placebo controlled study will be performed in hypertensive patients, aged between 40 and 65 years-old, in regular use of thiazidic diuretic as antihypertensive monotherapy,. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness.

Analysis: Data will be expressed as mean±epm. Statistical analysis will be performed using software Prism® (GraphPad, version 5.0). Continuous variables in each group will be compared using "t test", and P<0.05 will be considered statistically significant.

Description:

The main objective of this study is to evaluate whether magnesium supplementation is associated with improved blood pressure control and whether it has beneficial effects on the vascular structure and function in non-diabetic hypertensive patients who are receiving r diuretic therapy.

Patients will be evaluated in a prospective, randomized, double-blind study and will be admitted to the study if they reach all the inclusion criteria and no exclusion criteria.

In this study, magnesium chelate was chosen because of its better absorption rate. The dosages are different in many protocols but in this project the patients will receive 600 mg of magnesium element daily divided in 300 mg twice a day. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Women aged between 40 and 65 years-old

• Hypertension with mild blood pressure elevation:

• Systolic BP between 140 and 159mmHg AND/OR

• Diastolic BP between 90 and 99 mmHg

• Antihypertensive monotherapy with daily use of thiazidic diuretic, at least in the last 30 days

• Signature of the Informed Consent by the patient or his legal representative

Exclusion Criteria:

• Evidences for secondary hypertension

• Hypertension in stage 2, SBP = 160mmHg and/or DBP = 100mmHg, before the beginning of supplementation

• Blood pressure > 180 x 100 mmHg in any phase of the study

• Body mass index > 35 kg/m2

• Diabetes Mellitus

• Renal disease presenting glomerular filtration rate < 60ml/min

• Coronary artery disease clinically evident with previous episode of myocardial infarction and/or myocardial revascularization

• Clinical signs of heart failure

• History of stroke

• Any condition, disease or therapy that, under investigator's opinion, may influence objectives, results, or put in risk the safety of the patients.

• Pregnancy

• Patients should not be taking any mineral or vitamin supplements

• Gastrointestinal conditions

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Endothelial Dysfunction
• Hypertension

Intervention

Dietary Supplement:
• magnesium
Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
• placebo
Two capsules of placebo per oral twice a day

Locations

Country	Name	City	State
Brazil	Department of Clinical Medicine, State University of Rio de Janeiro	Rio de Janeiro	RJ

Sponsors (3)

Lead Sponsor	Collaborator
Rio de Janeiro State University	Conselho Nacional de Desenvolvimento Científico e Tecnológico, Rio de Janeiro State Research Supporting Foundation (FAPERJ)

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of vascular function		six months	No
Secondary	Improvement of vascular structure and blood pressure		six months	No